FY2024 Earnings Estimate for Balchem Issued By HC Wainwright

Balchem Co. (NASDAQ:BCPC) – HC Wainwright raised their FY2024 earnings per share (EPS) estimates for shares of Balchem in a research note issued on Monday, November 4th. HC Wainwright analyst R. Selvaraju now anticipates that the basic materials company will post earnings of $4.01 per share for the year, up from their previous estimate of $3.81. HC Wainwright has a “Buy” rating and a $190.00 price objective on the stock. The consensus estimate for Balchem’s current full-year earnings is $4.09 per share. HC Wainwright also issued estimates for Balchem’s Q4 2024 earnings at $1.10 EPS, Q1 2025 earnings at $1.06 EPS, Q2 2025 earnings at $1.09 EPS, Q3 2025 earnings at $1.14 EPS, Q4 2025 earnings at $1.19 EPS and FY2025 earnings at $4.47 EPS.

Separately, StockNews.com upgraded shares of Balchem from a “hold” rating to a “buy” rating in a research report on Monday, October 28th.

Balchem Trading Up 1.6 %

BCPC opened at $175.31 on Wednesday. The firm has a 50 day simple moving average of $171.75 and a 200 day simple moving average of $163.64. Balchem has a fifty-two week low of $116.84 and a fifty-two week high of $186.03. The company has a market cap of $5.70 billion, a price-to-earnings ratio of 47.13, a price-to-earnings-growth ratio of 5.25 and a beta of 0.65. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.98 and a quick ratio of 1.90.

Institutional Trading of Balchem

A number of hedge funds have recently modified their holdings of BCPC. Vanguard Group Inc. increased its stake in Balchem by 3.8% in the first quarter. Vanguard Group Inc. now owns 3,935,935 shares of the basic materials company’s stock valued at $609,873,000 after purchasing an additional 144,423 shares in the last quarter. Conestoga Capital Advisors LLC lifted its holdings in Balchem by 1.8% during the third quarter. Conestoga Capital Advisors LLC now owns 1,175,569 shares of the basic materials company’s stock worth $206,900,000 after acquiring an additional 20,360 shares in the last quarter. Geneva Capital Management LLC increased its holdings in shares of Balchem by 1.7% in the third quarter. Geneva Capital Management LLC now owns 779,869 shares of the basic materials company’s stock worth $137,257,000 after acquiring an additional 12,750 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Balchem by 0.9% during the second quarter. Dimensional Fund Advisors LP now owns 697,461 shares of the basic materials company’s stock worth $107,372,000 after purchasing an additional 5,977 shares during the period. Finally, Congress Asset Management Co. grew its position in shares of Balchem by 12.4% in the 3rd quarter. Congress Asset Management Co. now owns 301,440 shares of the basic materials company’s stock valued at $53,053,000 after purchasing an additional 33,373 shares during the period. 87.91% of the stock is currently owned by institutional investors and hedge funds.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.